ERBB2 and non-small cell lung carcinoma: Early targeted therapy for HER2 mutations in NSCLC patients primarily involved pan-HER-TKIs such as afatinib (205–208), daclatinib (209), neratinib (210), poziotinib (211), and pyrotinib.